Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Amicus Therapeutics is raising $199,916,500.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, John Crowley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amicus Therapeutics
We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA.

To learn more about Amicus Therapeutics, visit http://www.amicustherapeutics.com/

Contact:
John Crowley, President and Chief Executive Officer
215-921-7600
https://www.linkedin.com/in/john-f-crowley-540aa49/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved